Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Multimeric-001 + TIV
- Development stage
- Unknown
- Lead developer
- Scinai Immunotherapeutics
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Multimeric-001 + TIV is a prime-boost influenza vaccine regimen developed by BiondVax Pharmaceuticals (now Scinai Immunotherapeutics). The regimen consists of Multimeric-001 (M-001), a recombinant protein subunit vaccine containing nine conserved linear epitopes from the hemagglutinin (HA), nucleoprotein (NP), and matrix 1 (M1) proteins of influenza A and B strains, administered as a primer followed by a standard trivalent inactivated influenza vaccine (TIV) boost. This strategy is designed to enhance the breadth and magnitude of the immune response, particularly in the elderly, by activating both humoral and cellular immunity against conserved viral regions to provide cross-strain protection.
- Other names
- Multimeric Multi-Epitope Polypeptide Influenza VaccineM-001 + TIV
02
Targets
M1 (Muscarinic acetylcholine receptor M1)NP (Taï Forest ebolavirus nucleoprotein)HA (Hemagglutinin)
Beyond the preview
Go deeper on Multimeric-001 + TIV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Multimeric-001 + TIV.